Capital IdeasTM

Investment insights from Capital Group

Categories
ヘルスケア
Is technology man’s best medicine?
Matt Reynolds
Investment Director

A misaligned delivery model and lack of cure for major diseases are two of the biggest issues plaguing modern health care today.


Most doctors operate in a traditional fee-for-service model, getting paid based on volume. But the more patients they see, the more it reduces the time they can spend on every patient. This could potentially lead to a higher chance of misdiagnosis, mistakes and the tendency to only treat immediate illness or symptoms.


Many diseases come with significant health costs but the strain they place on economies can also be huge. In the US alone, 90% of the nation's US$4.3 trillion annual health care expenditures are for people with chronic2 and mental health conditions.


However, the emergence of value-based systems and advancements in data analytics and artificial intelligence (AI) could just be what the doctor ordered


In this paper, investment director Matt Reynolds outlines some of the key investment opportunities that are being unlocked by technological breakthroughs across a patient’s journey.


Unlocking innovative solutions along a patient’s journey

Unlocking innovative solutions along a patient’s journey

With global health care spending expected to reach US$10.6 trillion in 20303 (from US$9 trillion in 2022), the amount of resources that could be freed up, if a solution to the sector’s longstanding issues can be found, is potentially staggering. Similarly, the financial benefits could also be huge for companies that are able to conjure innovative solutions to these structural issues.


1. Data as at 15 December 2021. Source: National Health Expenditure Data: Historical. Center for Medicare & Medicaid Services
2. Referring to conditions that last more than a year and require ongoing medical attention
3. Data as at 20 October 2022. Source: Global Health Data Exchange (GHDx)



Matt Reynolds is an investment director at Capital Group. He has 31 years of investment industry experience and has been with Capital Group for five years. Prior to joining Capital, Matt worked as head of Australian equities at Colonial First State Global Asset Management. He holds a bachelor's degree in economics from The University of Sydney. He also holds the Chartered Financial Analyst® designation. Matt is based in Sydney.


過去の実績は将来の成果を保証するものではありません。投資の価値および投資収益は減少することも増加することもあり、当初投資額の一部または全部を失うことがあります。本情報は投資、税務もしくはその他の助言の提供、または証券の売買の勧誘を意図するものではありません。

個人に帰属する記述は、その個人の出版日現在の意見を述べたものであり、必ずしもキャピタル・グループまたはその関連会社の意見を反映したものではありません。特に明記がない限り、すべての情報は記載された日付現在のものです。一部の情報は第三者から取得したものであり、そのため、かかる情報の信頼性については保証いたしません。